-
Je něco špatně v tomto záznamu ?
Protease Inhibition-An Established Strategy to Combat Infectious Diseases
D. Sojka, P. Šnebergerová, L. Robbertse
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články, přehledy
Grantová podpora
20-05736S
Grantová Agentura České Republiky
CZ.02.1.01/0.0/0.0/16_019/0000759
Ministerstvo Školství, Mládeže a Tělovýchovy
NLK
Directory of Open Access Journals
od 2000
Free Medical Journals
od 2000
Freely Accessible Science Journals
od 2000
PubMed Central
od 2007
Europe PubMed Central
od 2007
ProQuest Central
od 2000-03-01
Open Access Digital Library
od 2000-01-01
Open Access Digital Library
od 2007-01-01
Health & Medicine (ProQuest)
od 2000-03-01
ROAD: Directory of Open Access Scholarly Resources
od 2000
PubMed
34071206
DOI
10.3390/ijms22115762
Knihovny.cz E-zdroje
- MeSH
- aspartátové endopeptidasy metabolismus MeSH
- COVID-19 enzymologie metabolismus MeSH
- farmakoterapie COVID-19 MeSH
- inhibitory proteas farmakologie MeSH
- lidé MeSH
- malárie farmakoterapie enzymologie metabolismus MeSH
- Plasmodium falciparum účinky léků patogenita MeSH
- proteasomový endopeptidasový komplex účinky léků MeSH
- SARS-CoV-2 účinky léků patogenita MeSH
- vyvíjení léků metody MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Therapeutic agents with novel mechanisms of action are urgently needed to counter the emergence of drug-resistant infections. Several decades of research into proteases of disease agents have revealed enzymes well suited for target-based drug development. Among them are the three recently validated proteolytic targets: proteasomes of the malarial parasite Plasmodium falciparum, aspartyl proteases of P. falciparum (plasmepsins) and the Sars-CoV-2 viral proteases. Despite some unfulfilled expectations over previous decades, the three reviewed targets clearly demonstrate that selective protease inhibitors provide effective therapeutic solutions for the two most impacting infectious diseases nowadays-malaria and COVID-19.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21018554
- 003
- CZ-PrNML
- 005
- 20210830100132.0
- 007
- ta
- 008
- 210728s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/ijms22115762 $2 doi
- 035 __
- $a (PubMed)34071206
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Sojka, Daniel $u Biology Centre, Institute of Parasitology, Academy of Sciences of the Czech Republic, Branišovská 1160/31, CZ-37005 České Budějovice, Czech Republic
- 245 10
- $a Protease Inhibition-An Established Strategy to Combat Infectious Diseases / $c D. Sojka, P. Šnebergerová, L. Robbertse
- 520 9_
- $a Therapeutic agents with novel mechanisms of action are urgently needed to counter the emergence of drug-resistant infections. Several decades of research into proteases of disease agents have revealed enzymes well suited for target-based drug development. Among them are the three recently validated proteolytic targets: proteasomes of the malarial parasite Plasmodium falciparum, aspartyl proteases of P. falciparum (plasmepsins) and the Sars-CoV-2 viral proteases. Despite some unfulfilled expectations over previous decades, the three reviewed targets clearly demonstrate that selective protease inhibitors provide effective therapeutic solutions for the two most impacting infectious diseases nowadays-malaria and COVID-19.
- 650 _2
- $a aspartátové endopeptidasy $x metabolismus $7 D016282
- 650 _2
- $a COVID-19 $x enzymologie $x metabolismus $7 D000086382
- 650 _2
- $a vyvíjení léků $x metody $7 D000076722
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a malárie $x farmakoterapie $x enzymologie $x metabolismus $7 D008288
- 650 _2
- $a Plasmodium falciparum $x účinky léků $x patogenita $7 D010963
- 650 _2
- $a inhibitory proteas $x farmakologie $7 D011480
- 650 _2
- $a proteasomový endopeptidasový komplex $x účinky léků $7 D046988
- 650 _2
- $a SARS-CoV-2 $x účinky léků $x patogenita $7 D000086402
- 650 _2
- $a farmakoterapie COVID-19 $7 D000093485
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Šnebergerová, Pavla $u Biology Centre, Institute of Parasitology, Academy of Sciences of the Czech Republic, Branišovská 1160/31, CZ-37005 České Budějovice, Czech Republic $u Faculty of Science, University of South Bohemia in České Budějovice, Branišovská 1760c, CZ-37005 České Budějovice, Czech Republic
- 700 1_
- $a Robbertse, Luïse $u Biology Centre, Institute of Parasitology, Academy of Sciences of the Czech Republic, Branišovská 1160/31, CZ-37005 České Budějovice, Czech Republic
- 773 0_
- $w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 22, č. 11 (2021)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34071206 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830100132 $b ABA008
- 999 __
- $a ok $b bmc $g 1689600 $s 1139000
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 22 $c 11 $e 20210528 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
- GRA __
- $a 20-05736S $p Grantová Agentura České Republiky
- GRA __
- $a CZ.02.1.01/0.0/0.0/16_019/0000759 $p Ministerstvo Školství, Mládeže a Tělovýchovy
- LZP __
- $a Pubmed-20210728